Last10K.com

Ac Immune Sa (ACIU) SEC Filing 6-K Foreign Issuer Report for the period ending Friday, September 30, 2022

Ac Immune Sa

HISTORY TOOLS
CIK: 1651625 Ticker: ACIU

View differences made from one to another to evaluate Ac Immune Sa's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ac Immune Sa.

Continue

Assess how Ac Immune Sa's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ac Immune Sa's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 6-K Foreign Issuer Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Changes In Equity
Condensed Consolidated Statements Of Comprehensive Income/(Loss)
Condensed Consolidated Statements Of Income/(Loss)
Accrued Expenses
Accrued Expenses (Details)
Accrued Expenses (Tables)
Basis Of Preparation And Changes To The Company's Accounting Policies
Basis Of Preparation And Changes To The Company's Accounting Policies (Policies)
Basis Of Preparation And Changes To The Company's Accounting Policies (Tables)
Basis Of Preparation And Changes To The Company's Accounting Policies - Functional And Reporting Currency (Details)
Basis Of Preparation And Changes To The Company's Accounting Policies - Going Concern (Details)
Cash And Cash Equivalents And Financial Assets
Cash And Cash Equivalents And Financial Assets (Details)
Cash And Cash Equivalents And Financial Assets (Tables)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents (Details)
Cash And Cash Equivalents And Financial Assets, Cash And Cash Equivalents And Short-Term Financial Assets (Details)
Contract Revenues And Other Operating Income
Contract Revenues And Other Operating Income (Tables)
Contract Revenues And Other Operating Income - Changes In Contract Assets And Liabilities (Details)
Contract Revenues And Other Operating Income - Grant From The Target Als Foundation (Details)
Contract Revenues And Other Operating Income - Grants From The Michael J. Fox Foundation (Details)
Contract Revenues And Other Operating Income - Licensing And Collaboration Agreement (Details)
Corporate Information
Corporate Information (Details)
Finance Result, Net
Finance Results, Net (Details)
Intangible Assets
Intangible Assets (Details)
Intangible Assets (Tables)
Loss Per Share
Loss Per Share (Details)
Loss Per Share (Tables)
Net Employee Defined Benefit Liabilities
Net Employee Defined Benefit Liabilities (Details)
Prepaid Expenses
Prepaid Expenses (Details)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Right-Of-Use Assets, Long-Term Financial Assets And Lease Liabilities
Right-Of-Use Assets, Long-Term Financial Assets And Lease Liabilities (Details)
Right-Of-Use Assets, Long-Term Financial Assets And Lease Liabilities (Tables)
Right-Of-Use Assets, Long-Term Financial Assets And Lease Liabilities - Contractual Undiscounted Cash Flows For Lease Obligations (Details)
Right-Of-Use Assets, Long-Term Financial Assets And Lease Liabilities - Statement Of Income/(Loss) And Cash Flow (Details)
Subsequent Events
Summary Of Contract Revenues And Other Operating Income (Details)
Treasury Shares
Treasury Shares (Details)

Material Contracts, Statements, Certifications & more

Ac Immune Sa provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Exhibit 99.2: Additional Exhibits
Exhibit 99.3: Additional Exhibits
Ticker: ACIU
CIK: 1651625
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001104659-22-112189
Submitted to the SEC: Fri Oct 28 2022 8:00:49 AM EST
Accepted by the SEC: Fri Oct 28 2022
Period: Friday, September 30, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aciu/0001104659-22-112189.htm